TY - JOUR
T1 - Stable gene transfer and expression in cord blood-derived CD34+ hematopoietic stem and progenitor cells by a hyperactive Sleeping Beauty transposon system
AU - Xue, Xingkui
AU - Huang, Xin
AU - Nodland, Sonja E.
AU - Mátés, Lajos
AU - Ma, Linan
AU - Izsvák, Zsuzsanna
AU - Ivics, Zoltán
AU - LeBien, Tucker W.
AU - McIvor, R. Scott
AU - Wagner, John E.
AU - Zhou, Xianzheng
PY - 2009
Y1 - 2009
N2 - Here we report stable gene transfer in cord blood-derived CD34+ hematopoietic stem cells using a hyperactive nonviral Sleeping Beauty (SB) transposase (SB100X). In colony-forming assays, SB100X mediated the highest efficiency (24%) of stable Discosoma sp red fluorescent protein (DsRed) reporter gene transfer in committed hematopoietic progenitors compared with both the early-generation hyperactive SB11 transposase and the piggyBac transposon system (1.23% and 3.8%, respectively). In vitro differentiation assays further demonstrated that SB100X-transfected CD34+ cells can develop into DsRed+ CD4+CD8+ T (3.17%-21.84%; median, 7.97%), CD19+ B (3.83%-18.66%; median, 7.84%), CD56 +CD3- NK (3.53%-79.98%; median, 7.88%), and CD33 + myeloid (7.59%-15.63%; median, 9.48%) cells. SB100X-transfected CD34+ cells achieved approximately 46% engraftment in NOD-scid IL;cnull (NOG)mice.Twelve weeks after transplantation, 0.57% to 28.96% (median, 2.79%) and 0.49% to 34.50% (median, 5.59%) of total human CD45+ cells in the bone marrow and spleen expressed DsRed, including CD19+ B, CD14+ monocytoid, and CD33+ myeloid cell lineages. Integration site analysis revealedSBtransposon sequences in thehumanchromosomes of in vitro differentiated T, B, NK, and myeloid cells, as well as in human CD45+ cells isolated from bone marrow and spleen of transplanted NOG mice. Our results support the continuing development of SB-based gene transfer into humanhematopoietic stem cells as a modality for gene therapy.
AB - Here we report stable gene transfer in cord blood-derived CD34+ hematopoietic stem cells using a hyperactive nonviral Sleeping Beauty (SB) transposase (SB100X). In colony-forming assays, SB100X mediated the highest efficiency (24%) of stable Discosoma sp red fluorescent protein (DsRed) reporter gene transfer in committed hematopoietic progenitors compared with both the early-generation hyperactive SB11 transposase and the piggyBac transposon system (1.23% and 3.8%, respectively). In vitro differentiation assays further demonstrated that SB100X-transfected CD34+ cells can develop into DsRed+ CD4+CD8+ T (3.17%-21.84%; median, 7.97%), CD19+ B (3.83%-18.66%; median, 7.84%), CD56 +CD3- NK (3.53%-79.98%; median, 7.88%), and CD33 + myeloid (7.59%-15.63%; median, 9.48%) cells. SB100X-transfected CD34+ cells achieved approximately 46% engraftment in NOD-scid IL;cnull (NOG)mice.Twelve weeks after transplantation, 0.57% to 28.96% (median, 2.79%) and 0.49% to 34.50% (median, 5.59%) of total human CD45+ cells in the bone marrow and spleen expressed DsRed, including CD19+ B, CD14+ monocytoid, and CD33+ myeloid cell lineages. Integration site analysis revealedSBtransposon sequences in thehumanchromosomes of in vitro differentiated T, B, NK, and myeloid cells, as well as in human CD45+ cells isolated from bone marrow and spleen of transplanted NOG mice. Our results support the continuing development of SB-based gene transfer into humanhematopoietic stem cells as a modality for gene therapy.
UR - http://www.scopus.com/inward/record.url?scp=70349320475&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=70349320475&partnerID=8YFLogxK
U2 - 10.1182/blood-2009-03-210005
DO - 10.1182/blood-2009-03-210005
M3 - Article
C2 - 19414858
AN - SCOPUS:70349320475
SN - 0006-4971
VL - 114
SP - 1319
EP - 1330
JO - Blood
JF - Blood
IS - 7
ER -